Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-04

AUTHORS

George Dranitsaris, Sasha Mazzarello, Stephanie Smith, Lisa Vandermeer, Nathaniel Bouganim, Mark Clemons

ABSTRACT

PURPOSE: The objective of this exploratory analysis was to determine if individual patient risk factors could be used to optimize chemotherapy-induced nausea and vomiting (CINV). METHODS: Through validated risk prediction models which quantify patient risk factors, 152 patients with early-stage breast cancer scheduled to received adjuvant anthracycline-based chemotherapy were categorized as being at low (level 0) or high-risk (level 1) for CINV. Prior to the first cycle of chemotherapy, low-risk patients received ondansetron and dexamethasone, while high-risk level 1 patients also received aprepitant. For subsequent cycles, patients who experienced CINV had their antiemetics changed in a stepwise manner to level 2 (extended-duration dexamethasone) or level 3 (extended-duration dexamethasone and low-dose olanzapine). RESULTS: The study enrolled 152 patients who received 484 cycles of chemotherapy. Forty patient cycles were classified as low risk (level 0) compared to 201, 162 and 81 that were classified as high-risk levels 1, 2 and 3, respectively. Complete control of acute and delayed vomiting was comparable and was achieved in over 85 % of patients across all risk levels (p = 0.56 and p = 0.99). In contrast, complete control of acute and delayed nausea was reduced in risk levels 1 to 3 compared to level 0 (acute = 51.2, 58.0, 45.7 vs. 70.0 %; p = 0.013)-(delayed = 32.8, 45.7, 34.6 vs. 62.5 %; p < 0.001). CONCLUSIONS: Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control. More... »

PAGES

1563-1569

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00520-015-2944-x

DOI

http://dx.doi.org/10.1007/s00520-015-2944-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028609174

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26381427


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiemetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dexamethasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Morpholines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nausea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ondansetron", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment (Health Care)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Guidelines as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vomiting", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ottawa Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "The Ottawa Hospital Cancer Centre, Ottawa, Canada", 
            "283 Danforth Ave, Suite 448, M4K 1N2, Toronto, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dranitsaris", 
        "givenName": "George", 
        "id": "sg:person.01036510774.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036510774.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "The Ottawa Hospital Cancer Centre, Ottawa, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mazzarello", 
        "givenName": "Sasha", 
        "id": "sg:person.0737376756.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737376756.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "The Ottawa Hospital Cancer Centre, Ottawa, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Stephanie", 
        "id": "sg:person.0651052101.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651052101.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "The Ottawa Hospital Cancer Centre, Ottawa, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vandermeer", 
        "givenName": "Lisa", 
        "id": "sg:person.0761055556.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761055556.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "The Ottawa Hospital Cancer Centre, Ottawa, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bouganim", 
        "givenName": "Nathaniel", 
        "id": "sg:person.01121740556.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121740556.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "The Ottawa Hospital Cancer Centre, Ottawa, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clemons", 
        "givenName": "Mark", 
        "id": "sg:person.01216107435.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216107435.90"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mdl019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007120853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.31.7859", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012116655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.34.4614", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014939429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00365579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017912982", 
          "https://doi.org/10.1007/bf00365579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-015-0786-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024417690", 
          "https://doi.org/10.1007/s10147-015-0786-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027015824"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029598491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3747/co.19.1074", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032134344"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-014-2138-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032627889", 
          "https://doi.org/10.1007/s00520-014-2138-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2010.10.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034049872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035398669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejon.2004.03.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035623421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-012-1710-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038084962", 
          "https://doi.org/10.1007/s00520-012-1710-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-003-0482-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038839491", 
          "https://doi.org/10.1007/s00520-003-0482-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.4451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042630049"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2015.3730", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048305164"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.suponc.2012.05.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054750673"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077181555", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-04", 
    "datePublishedReg": "2016-04-01", 
    "description": "PURPOSE: The objective of this exploratory analysis was to determine if individual patient risk factors could be used to optimize chemotherapy-induced nausea and vomiting (CINV).\nMETHODS: Through validated risk prediction models which quantify patient risk factors, 152 patients with early-stage breast cancer scheduled to received adjuvant anthracycline-based chemotherapy were categorized as being at low (level 0) or high-risk (level 1) for CINV. Prior to the first cycle of chemotherapy, low-risk patients received ondansetron and dexamethasone, while high-risk level 1 patients also received aprepitant. For subsequent cycles, patients who experienced CINV had their antiemetics changed in a stepwise manner to level 2 (extended-duration dexamethasone) or level 3 (extended-duration dexamethasone and low-dose olanzapine).\nRESULTS: The study enrolled 152 patients who received 484 cycles of chemotherapy. Forty patient cycles were classified as low risk (level 0) compared to 201, 162 and 81 that were classified as high-risk levels 1, 2 and 3, respectively. Complete control of acute and delayed vomiting was comparable and was achieved in over 85 % of patients across all risk levels (p = 0.56 and p = 0.99). In contrast, complete control of acute and delayed nausea was reduced in risk levels 1 to 3 compared to level 0 (acute = 51.2, 58.0, 45.7 vs. 70.0 %; p = 0.013)-(delayed = 32.8, 45.7, 34.6 vs. 62.5 %; p < 0.001).\nCONCLUSIONS: Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00520-015-2944-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1103473", 
        "issn": [
          "0941-4355", 
          "1433-7339"
        ], 
        "name": "Supportive Care in Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "name": "Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors", 
    "pagination": "1563-1569", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8849158ede53a9841b9474d00a520ef059919f0e1496932ccddcf16878717d09"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26381427"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9302957"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00520-015-2944-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028609174"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00520-015-2944-x", 
      "https://app.dimensions.ai/details/publication/pub.1028609174"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00520-015-2944-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00520-015-2944-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00520-015-2944-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00520-015-2944-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00520-015-2944-x'


 

This table displays all metadata directly associated to this object as RDF triples.

227 TRIPLES      21 PREDICATES      63 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00520-015-2944-x schema:about N0654964522b74d23818095d811d033f4
2 N12ac7faab6f24a94886a3de447719302
3 N4972472ab34c4effbf709f6c26ea61b8
4 N642e8d9d057e483a80b2e66deece88bc
5 N74acbe9300d848189de7a506272684ed
6 N8a7e18772d5d479e80e3af104aac7348
7 N8f2fb830bec347a499ebdcd14db5be9d
8 N97d9de2717444f7bb188d507bb410a93
9 N9ac4efc8872d4fc3807170abe0bce45a
10 Na8c8efdb16844aefb91124ccd1b0c4e1
11 Nafe9c7c845734a32abf74622000343cd
12 Nb8ecefe5670545e38af42d4465a9e267
13 Nbbf6d859646444fa986f5c1be22717d0
14 Nd32bf95d39254f64af4bc0c84a5f8309
15 Nf7efad7d24db4070bd4c1409b20085d7
16 Nf895d15eaec14f8d88b539b89286cd80
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N246a888524974d4b9b11337ecb922ec3
20 schema:citation sg:pub.10.1007/bf00365579
21 sg:pub.10.1007/s00520-003-0482-4
22 sg:pub.10.1007/s00520-012-1710-6
23 sg:pub.10.1007/s00520-014-2138-y
24 sg:pub.10.1007/s10147-015-0786-7
25 https://app.dimensions.ai/details/publication/pub.1077181555
26 https://doi.org/10.1001/jamaoncol.2015.3730
27 https://doi.org/10.1016/j.ejca.2010.10.013
28 https://doi.org/10.1016/j.ejon.2004.03.006
29 https://doi.org/10.1016/j.suponc.2012.05.001
30 https://doi.org/10.1093/annonc/mdl019
31 https://doi.org/10.1093/annonc/mdp160
32 https://doi.org/10.1093/annonc/mds541
33 https://doi.org/10.1093/annonc/mdu110
34 https://doi.org/10.1200/jco.2006.06.4451
35 https://doi.org/10.1200/jco.2010.31.7859
36 https://doi.org/10.1200/jco.2010.34.4614
37 https://doi.org/10.3747/co.19.1074
38 schema:datePublished 2016-04
39 schema:datePublishedReg 2016-04-01
40 schema:description PURPOSE: The objective of this exploratory analysis was to determine if individual patient risk factors could be used to optimize chemotherapy-induced nausea and vomiting (CINV). METHODS: Through validated risk prediction models which quantify patient risk factors, 152 patients with early-stage breast cancer scheduled to received adjuvant anthracycline-based chemotherapy were categorized as being at low (level 0) or high-risk (level 1) for CINV. Prior to the first cycle of chemotherapy, low-risk patients received ondansetron and dexamethasone, while high-risk level 1 patients also received aprepitant. For subsequent cycles, patients who experienced CINV had their antiemetics changed in a stepwise manner to level 2 (extended-duration dexamethasone) or level 3 (extended-duration dexamethasone and low-dose olanzapine). RESULTS: The study enrolled 152 patients who received 484 cycles of chemotherapy. Forty patient cycles were classified as low risk (level 0) compared to 201, 162 and 81 that were classified as high-risk levels 1, 2 and 3, respectively. Complete control of acute and delayed vomiting was comparable and was achieved in over 85 % of patients across all risk levels (p = 0.56 and p = 0.99). In contrast, complete control of acute and delayed nausea was reduced in risk levels 1 to 3 compared to level 0 (acute = 51.2, 58.0, 45.7 vs. 70.0 %; p = 0.013)-(delayed = 32.8, 45.7, 34.6 vs. 62.5 %; p < 0.001). CONCLUSIONS: Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N15176307acdf4de691c45ac906280baa
45 N454605b432b1402894e10cd8cd715aeb
46 sg:journal.1103473
47 schema:name Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors
48 schema:pagination 1563-1569
49 schema:productId N0e3d549bc5ac43dfbc6797de04d48efe
50 N19646b916d8c46d592852df8f9b5fbd7
51 N5190508fe5264efb89ccea1f9e7a4281
52 N7f98ea6125bd4c019c915bdc5241c1c8
53 N9ab9e859a0c74497964550aa675b8118
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028609174
55 https://doi.org/10.1007/s00520-015-2944-x
56 schema:sdDatePublished 2019-04-11T00:16
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Ncf2631f9f5294738ae8349bb822cac03
59 schema:url http://link.springer.com/10.1007%2Fs00520-015-2944-x
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N0654964522b74d23818095d811d033f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Breast Neoplasms
65 rdf:type schema:DefinedTerm
66 N0e3d549bc5ac43dfbc6797de04d48efe schema:name pubmed_id
67 schema:value 26381427
68 rdf:type schema:PropertyValue
69 N12ac7faab6f24a94886a3de447719302 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Humans
71 rdf:type schema:DefinedTerm
72 N15176307acdf4de691c45ac906280baa schema:issueNumber 4
73 rdf:type schema:PublicationIssue
74 N19646b916d8c46d592852df8f9b5fbd7 schema:name dimensions_id
75 schema:value pub.1028609174
76 rdf:type schema:PropertyValue
77 N246a888524974d4b9b11337ecb922ec3 rdf:first sg:person.01036510774.09
78 rdf:rest N4236186984954648822e9cae19a9f727
79 N4236186984954648822e9cae19a9f727 rdf:first sg:person.0737376756.24
80 rdf:rest N89cc01ff43a940d6bef2108d070ed5e3
81 N454605b432b1402894e10cd8cd715aeb schema:volumeNumber 24
82 rdf:type schema:PublicationVolume
83 N4972472ab34c4effbf709f6c26ea61b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Ondansetron
85 rdf:type schema:DefinedTerm
86 N5190508fe5264efb89ccea1f9e7a4281 schema:name doi
87 schema:value 10.1007/s00520-015-2944-x
88 rdf:type schema:PropertyValue
89 N642e8d9d057e483a80b2e66deece88bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Antineoplastic Agents
91 rdf:type schema:DefinedTerm
92 N7072560c795e4833b5fd92a877b5b328 rdf:first sg:person.01121740556.48
93 rdf:rest Nc7b1d104387c4f6fa9fa336171cd6334
94 N74acbe9300d848189de7a506272684ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Risk Factors
96 rdf:type schema:DefinedTerm
97 N7f98ea6125bd4c019c915bdc5241c1c8 schema:name nlm_unique_id
98 schema:value 9302957
99 rdf:type schema:PropertyValue
100 N89cc01ff43a940d6bef2108d070ed5e3 rdf:first sg:person.0651052101.37
101 rdf:rest N9eface991d404197ba128290c8c3f974
102 N8a7e18772d5d479e80e3af104aac7348 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Practice Guidelines as Topic
104 rdf:type schema:DefinedTerm
105 N8f2fb830bec347a499ebdcd14db5be9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Morpholines
107 rdf:type schema:DefinedTerm
108 N97d9de2717444f7bb188d507bb410a93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Adult
110 rdf:type schema:DefinedTerm
111 N9ab9e859a0c74497964550aa675b8118 schema:name readcube_id
112 schema:value 8849158ede53a9841b9474d00a520ef059919f0e1496932ccddcf16878717d09
113 rdf:type schema:PropertyValue
114 N9ac4efc8872d4fc3807170abe0bce45a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Vomiting
116 rdf:type schema:DefinedTerm
117 N9eface991d404197ba128290c8c3f974 rdf:first sg:person.0761055556.65
118 rdf:rest N7072560c795e4833b5fd92a877b5b328
119 Na8c8efdb16844aefb91124ccd1b0c4e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Aged
121 rdf:type schema:DefinedTerm
122 Nafe9c7c845734a32abf74622000343cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Dexamethasone
124 rdf:type schema:DefinedTerm
125 Nb8ecefe5670545e38af42d4465a9e267 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Female
127 rdf:type schema:DefinedTerm
128 Nbbf6d859646444fa986f5c1be22717d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Nausea
130 rdf:type schema:DefinedTerm
131 Nc7b1d104387c4f6fa9fa336171cd6334 rdf:first sg:person.01216107435.90
132 rdf:rest rdf:nil
133 Ncf2631f9f5294738ae8349bb822cac03 schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 Nd32bf95d39254f64af4bc0c84a5f8309 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Outcome Assessment (Health Care)
137 rdf:type schema:DefinedTerm
138 Nf7efad7d24db4070bd4c1409b20085d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Antiemetics
140 rdf:type schema:DefinedTerm
141 Nf895d15eaec14f8d88b539b89286cd80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Middle Aged
143 rdf:type schema:DefinedTerm
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
148 schema:name Oncology and Carcinogenesis
149 rdf:type schema:DefinedTerm
150 sg:journal.1103473 schema:issn 0941-4355
151 1433-7339
152 schema:name Supportive Care in Cancer
153 rdf:type schema:Periodical
154 sg:person.01036510774.09 schema:affiliation https://www.grid.ac/institutes/grid.412687.e
155 schema:familyName Dranitsaris
156 schema:givenName George
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036510774.09
158 rdf:type schema:Person
159 sg:person.01121740556.48 schema:affiliation https://www.grid.ac/institutes/grid.412687.e
160 schema:familyName Bouganim
161 schema:givenName Nathaniel
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121740556.48
163 rdf:type schema:Person
164 sg:person.01216107435.90 schema:affiliation https://www.grid.ac/institutes/grid.412687.e
165 schema:familyName Clemons
166 schema:givenName Mark
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216107435.90
168 rdf:type schema:Person
169 sg:person.0651052101.37 schema:affiliation https://www.grid.ac/institutes/grid.412687.e
170 schema:familyName Smith
171 schema:givenName Stephanie
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651052101.37
173 rdf:type schema:Person
174 sg:person.0737376756.24 schema:affiliation https://www.grid.ac/institutes/grid.412687.e
175 schema:familyName Mazzarello
176 schema:givenName Sasha
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737376756.24
178 rdf:type schema:Person
179 sg:person.0761055556.65 schema:affiliation https://www.grid.ac/institutes/grid.412687.e
180 schema:familyName Vandermeer
181 schema:givenName Lisa
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761055556.65
183 rdf:type schema:Person
184 sg:pub.10.1007/bf00365579 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017912982
185 https://doi.org/10.1007/bf00365579
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s00520-003-0482-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038839491
188 https://doi.org/10.1007/s00520-003-0482-4
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s00520-012-1710-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038084962
191 https://doi.org/10.1007/s00520-012-1710-6
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/s00520-014-2138-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1032627889
194 https://doi.org/10.1007/s00520-014-2138-y
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/s10147-015-0786-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024417690
197 https://doi.org/10.1007/s10147-015-0786-7
198 rdf:type schema:CreativeWork
199 https://app.dimensions.ai/details/publication/pub.1077181555 schema:CreativeWork
200 https://doi.org/10.1001/jamaoncol.2015.3730 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048305164
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.ejca.2010.10.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034049872
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.ejon.2004.03.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035623421
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/j.suponc.2012.05.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054750673
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1093/annonc/mdl019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007120853
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1093/annonc/mdp160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035398669
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1093/annonc/mds541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029598491
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1093/annonc/mdu110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027015824
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1200/jco.2006.06.4451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042630049
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1200/jco.2010.31.7859 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012116655
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1200/jco.2010.34.4614 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014939429
221 rdf:type schema:CreativeWork
222 https://doi.org/10.3747/co.19.1074 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032134344
223 rdf:type schema:CreativeWork
224 https://www.grid.ac/institutes/grid.412687.e schema:alternateName Ottawa Hospital
225 schema:name 283 Danforth Ave, Suite 448, M4K 1N2, Toronto, Ontario, Canada
226 The Ottawa Hospital Cancer Centre, Ottawa, Canada
227 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...